| Dr Arthur N Falk, MD | |
|
35 Hackett Blvd, Albany, NY 12208-3420 | |
| (518) 262-7193 | |
| (518) 264-0647 |
| Full Name | Dr Arthur N Falk |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 32 Years |
| Location | 35 Hackett Blvd, Albany, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1538169180 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | 194626 (New York) | Secondary |
| 2082S0099X | Plastic Surgery - Plastic Surgery Within The Head And Neck | 194626 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Albany Medical Center Hospital | Albany, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Albany Medical College | 1759293111 | 910 |
News Archive
News outlets report on how timing issues could impact whether the challenges to the health law make it to the Supreme Court in the next term, how messages regarding efforts to overhaul the health care system are playing in presidential primary states and how opposition to "Obamacare" is motivating one Republican to consider joining the presidential contest fray.
Monsanto Company and Limerick-based biotechnology firm, Stokes Bio Limited, announced today that they have entered into a licensing agreement and R&D collaboration, which is expected to help accelerate the pace of new advancements in plant breeding.
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced interim results from a Phase I clinical trial of its investigational drug candidate, recombinant human Interleukin-7 (CYT107), in the treatment of post-transplant patients with T-cell depleted (TCD) bone marrow or peripheral blood stem cell transplants.
Astellas Pharma Inc., a global pharmaceutical company, and OSI Pharmaceuticals, Inc., a biotechnology company primarily focused on the discovery, development and commercialization of molecular targeted therapies addressing medical needs in oncology, diabetes and obesity, today announced that they have entered into a definitive merger agreement under which Astellas will acquire OSI.
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have published research on how the knees of pigs compare to human knees at various stages of maturity - a finding that will advance research by this group and others on injury treatment in young people.
› Verified 2 days ago
| Entity Name | Ellis Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487644993 PECOS PAC ID: 5890607410 Enrollment ID: O20031103000406 |
News Archive
News outlets report on how timing issues could impact whether the challenges to the health law make it to the Supreme Court in the next term, how messages regarding efforts to overhaul the health care system are playing in presidential primary states and how opposition to "Obamacare" is motivating one Republican to consider joining the presidential contest fray.
Monsanto Company and Limerick-based biotechnology firm, Stokes Bio Limited, announced today that they have entered into a licensing agreement and R&D collaboration, which is expected to help accelerate the pace of new advancements in plant breeding.
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced interim results from a Phase I clinical trial of its investigational drug candidate, recombinant human Interleukin-7 (CYT107), in the treatment of post-transplant patients with T-cell depleted (TCD) bone marrow or peripheral blood stem cell transplants.
Astellas Pharma Inc., a global pharmaceutical company, and OSI Pharmaceuticals, Inc., a biotechnology company primarily focused on the discovery, development and commercialization of molecular targeted therapies addressing medical needs in oncology, diabetes and obesity, today announced that they have entered into a definitive merger agreement under which Astellas will acquire OSI.
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have published research on how the knees of pigs compare to human knees at various stages of maturity - a finding that will advance research by this group and others on injury treatment in young people.
› Verified 2 days ago
| Entity Name | Albany Medical College |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629008537 PECOS PAC ID: 1759293111 Enrollment ID: O20031125000386 |
News Archive
News outlets report on how timing issues could impact whether the challenges to the health law make it to the Supreme Court in the next term, how messages regarding efforts to overhaul the health care system are playing in presidential primary states and how opposition to "Obamacare" is motivating one Republican to consider joining the presidential contest fray.
Monsanto Company and Limerick-based biotechnology firm, Stokes Bio Limited, announced today that they have entered into a licensing agreement and R&D collaboration, which is expected to help accelerate the pace of new advancements in plant breeding.
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced interim results from a Phase I clinical trial of its investigational drug candidate, recombinant human Interleukin-7 (CYT107), in the treatment of post-transplant patients with T-cell depleted (TCD) bone marrow or peripheral blood stem cell transplants.
Astellas Pharma Inc., a global pharmaceutical company, and OSI Pharmaceuticals, Inc., a biotechnology company primarily focused on the discovery, development and commercialization of molecular targeted therapies addressing medical needs in oncology, diabetes and obesity, today announced that they have entered into a definitive merger agreement under which Astellas will acquire OSI.
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have published research on how the knees of pigs compare to human knees at various stages of maturity - a finding that will advance research by this group and others on injury treatment in young people.
› Verified 2 days ago
| Entity Name | Albany Medical College |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497921688 PECOS PAC ID: 1759293111 Enrollment ID: O20190320001621 |
News Archive
News outlets report on how timing issues could impact whether the challenges to the health law make it to the Supreme Court in the next term, how messages regarding efforts to overhaul the health care system are playing in presidential primary states and how opposition to "Obamacare" is motivating one Republican to consider joining the presidential contest fray.
Monsanto Company and Limerick-based biotechnology firm, Stokes Bio Limited, announced today that they have entered into a licensing agreement and R&D collaboration, which is expected to help accelerate the pace of new advancements in plant breeding.
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced interim results from a Phase I clinical trial of its investigational drug candidate, recombinant human Interleukin-7 (CYT107), in the treatment of post-transplant patients with T-cell depleted (TCD) bone marrow or peripheral blood stem cell transplants.
Astellas Pharma Inc., a global pharmaceutical company, and OSI Pharmaceuticals, Inc., a biotechnology company primarily focused on the discovery, development and commercialization of molecular targeted therapies addressing medical needs in oncology, diabetes and obesity, today announced that they have entered into a definitive merger agreement under which Astellas will acquire OSI.
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have published research on how the knees of pigs compare to human knees at various stages of maturity - a finding that will advance research by this group and others on injury treatment in young people.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Arthur N Falk, MD 35 Hackett Blvd, 2nd Flr, Albany, NY 12208-3420 Ph: (518) 262-7193 | Dr Arthur N Falk, MD 35 Hackett Blvd, Albany, NY 12208-3420 Ph: (518) 262-7193 |
News Archive
News outlets report on how timing issues could impact whether the challenges to the health law make it to the Supreme Court in the next term, how messages regarding efforts to overhaul the health care system are playing in presidential primary states and how opposition to "Obamacare" is motivating one Republican to consider joining the presidential contest fray.
Monsanto Company and Limerick-based biotechnology firm, Stokes Bio Limited, announced today that they have entered into a licensing agreement and R&D collaboration, which is expected to help accelerate the pace of new advancements in plant breeding.
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced interim results from a Phase I clinical trial of its investigational drug candidate, recombinant human Interleukin-7 (CYT107), in the treatment of post-transplant patients with T-cell depleted (TCD) bone marrow or peripheral blood stem cell transplants.
Astellas Pharma Inc., a global pharmaceutical company, and OSI Pharmaceuticals, Inc., a biotechnology company primarily focused on the discovery, development and commercialization of molecular targeted therapies addressing medical needs in oncology, diabetes and obesity, today announced that they have entered into a definitive merger agreement under which Astellas will acquire OSI.
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have published research on how the knees of pigs compare to human knees at various stages of maturity - a finding that will advance research by this group and others on injury treatment in young people.
› Verified 2 days ago
Dr. Francis J Cullen, MD Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 5 Palisades Dr, Suite 110, Albany, NY 12205 Phone: 518-482-7880 Fax: 518-482-7882 | |
Dr. James Lawrence Dolph, M.D. Plastic Surgery Medicare: Medicare Enrolled Practice Location: 319 S Manning Blvd, Suite 103, Albany, NY 12208 Phone: 518-482-7874 Fax: 518-482-7987 | |
Dr. David M Tauber, MD Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 5 Ulenski Dr, Albany, NY 12205 Phone: 518-724-2444 Fax: 518-724-2445 |